

Supplementary Information for:

**Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan**

Qianyun Liu<sup>1, 5</sup>, Qing Xiong<sup>1, 5</sup>, Fanghua Mei<sup>2, 5</sup>, Chengbao Ma<sup>1</sup>, Zhen Zhang<sup>1</sup>, Bing Hu<sup>2</sup>, Junqiang Xu<sup>2</sup>, Yongzhong Jiang<sup>2</sup>, Faxian Zhan<sup>2</sup>, Xianying Chen<sup>1</sup>, Ming Guo<sup>1</sup>, Xin Wang<sup>1</sup>, Yaohui Fang<sup>3</sup>, Shu Shen<sup>3</sup>, Yingle Liu<sup>1</sup>, Fang Liu<sup>1</sup>, Li Zhou<sup>1</sup>, Ke Xu<sup>1</sup>, Changwen Ke<sup>4</sup>, Fei Deng<sup>3</sup>, Kun Cai<sup>2</sup>✉, Huan Yan<sup>1</sup> ✉, Yu Chen<sup>1</sup> ✉, Ke Lan<sup>1</sup> ✉

<sup>1</sup>State Key Laboratory of Virology, Institute for Vaccine Research and Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, China.

<sup>2</sup>Hubei Provincial Center for Disease Control and Prevention, Wuhan, China.

<sup>3</sup>National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences.

<sup>4</sup>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.


<sup>5</sup>These authors contributed equally: Qianyun Liu, Qing Xiong, Fanghua Mei

✉e-mail: [ckreal@163.com](mailto:ckreal@163.com); [huanyan@whu.edu.cn](mailto:huanyan@whu.edu.cn); [chenyu@whu.edu.cn](mailto:chenyu@whu.edu.cn); [klan@whu.edu.cn](mailto:klan@whu.edu.cn)

**Extended data Fig. 1: The neutralizing activity of the convalescents' sera to WT-D614G and variants for NT<sub>50</sub> determination.**

**Extended data Table 1: The clinical records and sera reactivity to SARS-CoV-2 of the convalescents in this study.**

### Extended data Fig. 1



sample number	$NT_{50}$					
	WT-D614G	England	South Africa	Brazil	Nigeria	
Group 1	6	245.5	181.6	119.3	173.8	188.5
	24	263	158.1	107.5	171.4	180.1
	91	262.4	163.4	124.5	158.4	277.7
	99	129	93.78	74.42	93.78	166.3
	123	294	273	85.22	243.9	170.4
	124	354.1	227.2	113.9	309.4	183.2
	128	194.4	166.5	79.45	166.5	214.7
	143	421.9	453.7	137.5	338.3	217.6
Group 2	29	262.4	163.4	124.5	158.4	277.7
	41	194.4	166.5	79.45	166.5	214.7
	48	354.1	227.2	113.9	309.4	183.2
	72	245.5	181.6	119.3	173.8	188.5
	92	129	93.78	74.42	93.78	166.3
	133	294	273	85.22	243.9	170.4
	146	421.9	453.7	137.5	338.3	217.6
	222	263	158.1	107.5	171.4	180.1

**Extended data Table 1:**

Sample number	Gender	Age range	Illness severity	Anti-SARS-CoV-2-S IgM	Anti-SARS-CoV-2-S IgG	Anti-RBD IgG level (OD450)	Competitive ability of ACE2 to RBD binding (%)
1	male	35~39	critical	-	+	0.954	63.6%
2	female	40~44	mild	-	+	0.498	41.7%
3	male	55~59	mild	-	-	0.608	36.2%
4	female	above 74	mild	-	+	0.773	82.7%
5	female	70~74	asymptomatic	-	+	0.606	70.1%
6	female	65~69	mild	-	+	0.83	78.5%
7	male	50~54	mild	-	+	0.608	32.0%
8	female	65~69	mild	-	+	0.948	87.9%
9	female	50~54	mild	-	+	0.58	40.4%
10	male	above 74	normal	-	+	0.887	71.5%
12	male	35~39	mild	-	-	0.549	45.8%
13	female	above 74	mild	-	-	0.273	5.5%
14	female	50~54	normal	-	+	0.982	66.6%
15	male	65~69	mild	-	+	0.849	69.4%
16	male	55~59	normal	-	+	0.75	49.6%
17	female	70~74	mild	-	+	0.9	78.1%
18	female	55~59	severe	-	+	0.794	80.2%
19	male	60~64	mild	-	+	0.374	32.3%
20	female	65~69	severe	-	+	1.224	92.7%
21	female	35~39	mild	-	+	0.692	64.6%
22	female	60~64	mild	-	+	0.8	86.6%
23	male	65~69	severe	-	+	1.017	84.4%
24	male	above 74	mild	-	+	1.118	86.7%
25	female	60~64	mild	-	+	1.145	94.7%
26	male	35~39	mild	-	+	0.551	40.0%
27	female	70~74	mild	-	+	1.188	93.3%
28	female	60~64	normal	-	+	1.191	95.8%
29	female	60~64	mild	-	+	1.367	97.1%
30	female	60~64	asymptomatic	-	+	1.117	87.2%
31	male	65~69	severe	-	+	0.784	70.5%
32	male	60~64	severe	-	+	0.664	63.5%
33	female	65~69	mild	-	+	0.763	76.8%
34	male	65~69	normal	-	+	0.927	80.3%
35	female	60~64	normal	-	+	1.425	96.7%
36	male	65~69	severe	-	+	0.971	73.6%
37	female	70~74	mild	-	+	1.375	96.8%
38	male	40~44	normal	-	-	0.458	48.7%
39	female	55~59	normal	-	+	0.954	86.5%
40	male	35~39	normal	-	-	0.179	15.5%
41	female	70~74	normal	-	+	1.166	77.4%
42	female	60~64	severe	-	+	0.697	50.2%
43	female	50~54	mild	-	+	0.754	60.8%
44	male	65~69	severe	-	+	1.161	86.3%
45	male	above 74	severe	-	+	0.432	38.8%
46	female	55~59	normal	-	+	1.151	88.5%
47	male	55~59	normal	-	+	0.901	77.6%
48	female	55~59	mild	-	+	1.293	96.7%
49	female	50~54	normal	-	+	1.327	93.4%
50	male	70~74	normal	-	-	0.275	21.3%
51	female	45~49	severe	-	+	0.782	60.8%
52	male	55~59	severe	-	+	1.17	92.1%
53	male	70~74	severe	-	+	0.402	31.4%
54	female	65~69	mild	-	+	0.458	29.1%
55	female	65~69	severe	-	+	0.632	62.6%
56	female	40~44	normal	-	+	1.378	97.1%
57	male	45~49	severe	-	-	0.339	32.4%
58	male	55~59	mild	-	+	1.081	92.7%
59	male	20~29	asymptomatic	-	-	0.125	17.0%
60	male	65~69	normal	-	+	1.328	96.3%
61	female	60~64	critical	-	-	0.689	64.6%
62	male	55~59	severe	-	+	1.092	77.7%
63	female	60~64	normal	-	+	0.866	81.6%
64	female	60~64	mild	-	-	0.546	38.2%

Sample number	Gender	Age range	Illness severity	Anti-SARS-CoV-2-S IgM	Anti-SARS-CoV-2-S IgG	Anti-RBD IgG level (OD450)	Competitive ability of ACE2 to RBD binding (%)
65	female	60~64	severe	-	+	0.89	71.6%
66	female	55~59	normal	-	+	0.763	65.1%
67	female	55~59	severe	-	+	0.743	64.7%
68	male	above 74	mild	-	+	0.847	63.4%
69	male	30~34	normal	-	+	0.531	56.0%
70	male	70~74	normal	-	+	0.967	76.5%
71	female	70~74	normal	-	+	0.667	51.6%
72	female	40~44	normal	-	+	1.293	94.3%
73	male	50~54	mild	-	+	0.254	12.4%
74	female	50~54	normal	-	-	0.199	18.9%
75	male	55~59	severe	-	+	0.544	63.4%
76	male	65~69	normal	-	+	0.351	40.5%
77	female	20~29	mild	-	-	0.376	35.8%
78	female	65~69	mild	-	+	1.044	83.0%
79	male	50~54	mild	-	+	0.211	56.6%
80	female	55~59	normal	-	+	0.763	83.8%
81	female	65~69	mild	-	+	0.726	56.2%
82	female	60~64	mild	-	+	0.606	47.4%
83	female	55~59	normal	-	+	1.146	66.8%
84	male	45~49	mild	-	+	0.672	48.3%
85	female	45~49	normal	-	-	0.401	46.5%
86	male	60~64	severe	-	+	0.616	47.5%
87	female	45~49	mild	+	+	1.467	94.9%
88	male	45~49	normal	-	-	0.429	33.3%
89	female	50~54	mild	-	+	0.925	69.5%
90	female	50~54	normal	-	+	0.855	76.9%
91	male	55~59	mild	+	+	0.901	65.7%
92	female	55~59	critical	-	+	1.058	96.7%
93	female	50~54	mild	-	+	1.326	96.4%
94	male	55~59	normal	-	+	0.837	92.3%
95	male	55~59	severe	-	+	1.272	95.0%
96	female	50~54	normal	-	+	0.683	34.2%
97	male	20~29	mild	-	+	0.826	60.2%
98	male	55~59	severe	-	+	1.008	90.3%
99	female	60~64	mild	-	+	0.378	53.2%
100	female	50~54	normal	-	+	0.223	17.0%
101	male	40~44	normal	-	-	0.638	24.6%
102	female	45~49	normal	-	-	0.546	43.0%
103	female	55~59	asymptomatic	-	-	0.376	4.2%
104	male	50~54	severe	-	+	0.908	82.1%
105	female	50~54	normal	-	+	0.686	59.4%
106	male	40~44	critical	+	+	0.46	30.6%
107	female	40~44	normal	-	+	0.777	54.6%
108	male	65~69	mild	-	+	1.136	88.5%
109	male	20~29	mild	-	+	0.983	80.5%
110	male	60~64	mild	-	+	0.731	19.6%
111	female	65~69	normal	-	+	0.721	35.6%
112	female	35~39	severe	-	+	0.516	21.7%
113	male	55~59	mild	-	+	1.041	83.3%
115	female	20~29	mild	-	-	0.58	61.4%
116	male	55~59	severe	-	-	0.49	38.0%
117	male	55~59	mild	-	-	0.624	39.8%
118	female	65~69	mild	-	+	0.051	62.6%
119	female	35~39	mild	-	+	0.989	16.8%
120	female	65~69	severe	-	+	0.936	88.8%
121	female	50~54	normal	-	+	0.664	76.6%
122	female	20~29	mild	-	+	0.829	85.1%
123	female	50~54	normal	-	+	0.919	95.6%
124	male	55~59	mild	-	+	1.184	96.3%
125	male	60~64	normal	-	+	0.58	43.0%
126	male	65~69	normal	-	-	0.242	21.4%
127	male	60~64	normal	-	+	0.512	46.0%
128	female	65~69	normal	-	+	0.82	74.6%
129	male	60~64	mild	-	-	0.125	2.2%
130	male	60~64	severe	-	+	0.729	49.0%
131	male	70~74	mild	-	-	0.322	13.6%

Sample number	Gender	Age range	Illness severity	Anti-SARS-CoV-2-S IgM	Anti-SARS-CoV-2-S IgG	Anti-RBD IgG level (OD450)	Competitive ability of ACE2 to RBD binding (%)
132	female	70~74	mild	-	+	0.642	60.5%
133	male	70~74	mild	-	+	1.068	50.5%
134	male	50~54	normal	-	+	0.702	61.2%
135	female	55~59	mild	-	-	0.47	42.2%
136	male	45~49	mild	-	-	0.246	15.1%
137	female	55~59	normal	-	-	0.894	53.6%
138	female	65~69	mild	-	+	0.935	60.5%
139	male	30~34	mild	-	+	0.318	21.4%
140	male	60~64	normal	-	+	1.024	72.8%
141	male	35~39	normal	-	-	0.549	46.4%
142	female	40~44	normal	-	+	1.18	94.4%
143	female	65~69	mild	-	+	1.191	95.5%
144	female	60~64	normal	-	+	0.376	15.1%
145	male	60~64	mild	-	-	0.727	62.6%
146	female	55~59	mild	-	+	1.177	96.8%
147	female	65~69	severe	-	+	0.788	79.7%
148	female	55~59	mild	-	+	1.15	96.1%
149	female	50~54	normal	-	-	0.219	13.0%
150	female	30~34	mild	-	+	0.553	47.4%
151	male	40~44	severe	-	+	0.64	79.0%
152	male	60~64	mild	-	+	0.8	70.5%
153	male	60~64	asymptomatic	-	+	0.265	22.0%
154	male	30~34	normal	-	+	0.598	49.4%
155	female	40~44	normal	-	+	1.12	94.0%
156	female	55~59	normal	-	-	0.234	40.1%
157	female	20~29	mild	-	+	1.186	96.3%
158	male	30~34	mild	-	-	0.806	55.4%
159	female	55~59	mild	-	+	0.614	45.3%
160	female	55~59	normal	-	+	0.956	79.6%
161	male	above 74	mild	-	-	0.591	61.6%
162	female	above 74	normal	-	+	0.516	46.0%
163	female	70~74	mild	+	+	0.411	45.7%
164	female	65~69	normal	-	+	0.805	77.9%
165	male	70~74	severe	-	+	0.476	31.6%
166	female	70~74	critical	-	+	0.86	74.5%
167	female	60~64	severe	-	+	0.585	52.2%
168	female	45~49	critical	-	+	0.277	12.0%
169	female	40~44	mild	-	+	1.053	80.1%
170	male	65~69	severe	-	+	0.478	31.1%
171	female	65~69	severe	-	+	0.361	22.8%
172	male	40~44	severe	-	+	0.688	34.7%
173	male	above 74	normal	-	+	0.598	33.2%
174	male	65~69	mild	-	+	0.316	17.8%
175	male	65~69	mild	-	+	0.751	77.4%
176	female	65~69	mild	-	+	0.706	55.6%
177	female	70~74	mild	-	+	1.218	79.5%
178	female	70~74	mild	-	+	1.064	54.0%
179	male	30~34	mild	-	+	0.68	29.9%
180	female	55~59	normal	-	+	1.335	78.7%
181	male	70~74	severe	-	-	0.259	0.0%
182	female	60~64	normal	-	+	1.451	62.8%
183	female	above 74	normal	-	+	0.799	23.5%
184	male	50~54	mild	-	+	0.604	10.7%
185	male	65~69	normal	-	+	1.641	80.7%
186	male	55~59	mild	-	+	0.638	27.2%
187	female	65~69	normal	-	-	0.481	16.0%
188	male	35~39	mild	-	+	0.607	40.7%
189	male	60~64	severe	-	+	1.106	67.7%
190	female	60~64	normal	-	+	0.828	58.2%
191	male	60~64	critical	-	-	0.79	33.4%
192	male	50~54	normal	-	+	0.775	45.0%
193	female	50~54	mild	-	+	0.65	9.7%
194	male	30~34	normal	-	+	0.801	40.3%
195	male	35~39	mild	-	-	0.331	0.0%
196	male	70~74	mild	-	+	1.267	63.9%
197	female	65~69	severe	-	-	0.2	2.8%

Sample number	Gender	Age range	Illness severity	Anti-SARS-CoV-2-S IgM	Anti-SARS-CoV-2-S IgG	Anti-RBD IgG level (OD450)	Competitive ability of ACE2 to RBD binding (%)
198	female	55~59	normal	-	+	1.692	88.9%
199	female	20~29	normal	-	+	0.783	23.0%
200	male	60~64	severe	-	+	1.204	73.8%
201	male	60~64	severe	-	+	0.942	55.6%
202	female	60~64	mild	-	+	0.879	47.9%
203	female	60~64	critical	-	+	1.256	87.1%
204	male	30~34	severe	-	+	1.028	70.9%
205	female	60~64	critical	-	+	0.716	45.7%
206	male	65~69	normal	-	+	0.826	65.3%
207	male	65~69	severe	-	+	0.969	83.5%
208	female	above 74	mild	-	-	0.354	30.4%
209	female	65~69	mild	-	-	0.499	16.3%
210	female	60~64	severe	-	+	0.932	59.5%
211	female	55~59	severe	-	-	0.717	41.1%
212	female	35~39	normal	-	+	0.772	54.0%
213	male	55~59	asymptomatic	-	+	1.362	92.1%
214	female	60~64	normal	-	+	1.503	84.7%
215	female	65~69	mild	-	+	0.964	43.3%
216	male	65~69	critical	-	-	0.825	21.7%
217	male	65~69	severe	-	+	1.321	67.6%
218	female	65~69	normal	-	+	1.226	83.0%
219	male	65~69	normal	-	+	1.181	78.7%
220	male	60~64	severe	-	-	0.471	31.5%
221	female	30~34	mild	-	-	0.845	53.5%
222	male	65~69	normal	-	+	1.597	92.2%
223	male	65~69	normal	-	+	1.387	86.9%
224	male	70~74	severe	-	+	0.97	76.3%
225	female	70~74	normal	-	+	0.668	47.6%
226	female	65~69	mild	-	+	0.553	52.5%
227	male	70~74	mild	-	-	0.975	63.5%
228	female	above 74	asymptomatic	-	+	0.739	68.3%
229	male	65~69	severe	-	+	0.871	87.8%
230	male	55~59	asymptomatic	-	+	0.752	40.2%
231	male	30~34	normal	-	-	0.952	53.6%
232	male	above 74	mild	-	+	0.451	1.9%
233	female	55~59	mild	-	+	0.733	45.6%
234	male	65~69	mild	-	-	0.558	21.1%
235	female	40~44	mild	-	-	0.237	0.0%
236	male	20~29	normal	-	-	0.185	0.9%
237	male	50~54	normal	-	+	0.775	72.8%
238	male	45~49	mild	-	+	1.152	84.6%
239	male	70~74	mild	+	+	1.245	82.6%
240	female	70~74	mild	-	+	0.695	52.9%
241	male	60~64	normal	-	-	0.23	12.8%
242	female	20~29	mild	-	+	1.354	95.6%
243	female	60~64	mild	-	-	0.218	10.2%
244	male	70~74	mild	-	+	0.914	63.0%
245	male	45~49	mild	-	+	0.524	25.8%
246	male	60~64	mild	-	+	0.735	45.7%
247	female	60~64	mild	-	+	0.866	48.6%
248	female	above 74	normal	-	-	0.119	0.0%
249	male	60~64	normal	-	+	0.792	71.5%
250	female	70~74	mild	-	+	1.081	86.3%
NC-1	male	30~34	uninfected	-	-	0.119	untested
NC-2	male	30~34	uninfected	-	-	0.178	untested
NC-3	male	20~29	uninfected	-	-	0.124	untested
NC-4	female	20~29	uninfected	-	-	0.201	untested
NC-5	female	20~29	uninfected	-	-	0.048	untested
NC-6	male	35~39	uninfected	-	-	0.175	untested
NC-7	female	40~44	uninfected	-	-	0.101	untested
NC-8	female	55~59	uninfected	-	-	0.243	untested
NC-9	female	60~64	uninfected	-	-	0.153	untested
NC-10	male	45~49	uninfected	-	-	0.13	untested